Indeed, a retrospective analysis of serous ovarian cancer demonstrated 40.4% of the specimens to have strong CIP2A immunoreactivity and another 42.4% had weak positive staining (117). The gene discussed is CIP2A; the disease is ovarian serous adenocarcinoma.